COST EFFECTIVENESS OF ZOLEDRONIC ACID VS. PAMIDRONATE OR NO THERAPY FOR THE TREATMENT OF BONE METASTASES SECONDARY TO PROSTATE CANCER

被引：0
|
作者：
Carter, J. A. [1 ]
Bains, M. [2 ]
Chandiwana, D. [2 ]
Kaura, S. [3 ]
Botteman, M. F. [1 ]
机构：
[1] Pharmerit N Amer LLC, Bethesda, MD USA
[2] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[3] Novartis Pharmaceut, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A447 / A447
页数：1
相关论文
共 50 条
  • [21] Pamidronate and Zoledronic Acid in the Treatment of Paget's Disease of Bone
    Colina, Matteo
    Ciancio, Giovanni
    Trotta, Francesco
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1451 - 1456
  • [22] Randomized trial of denosumab versus zoledronic acid in prostate cancer patients with bone metastases and elevated bone turnover markers after receiving zoledronic acid therapy
    Bosserman, Linda
    Fizazi, Karim
    Lipton, Allan
    Rahim, Yasmin
    Suarez, Tirzo
    Fan, Michelle
    Wu, Ling
    Markus, Richard A.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 335 - 336
  • [23] Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China
    Yu, Zhanwu
    Liu, Yu
    Cui, Ying
    Ma, Rui
    Zhan, Huan
    Chen, Wendong
    Liu, Hongxu
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (07) : 487 - 495
  • [24] IMPACT OF ZOLEDRONIC ACID ON FRACTURES AND MORTALITY IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 284 - 285
  • [25] Efficacy of zoledronic acid in the treatment of bone metastases secondary to renal cell carcinoma
    Schulman, CC
    EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (05) : 40 - 45
  • [26] Cost-efficacy of zoledronic 4mg acid vs. pamidronate 90mg in the treatment of hypercalcemia of malignacy (HCM)
    Badia, X
    Slof, EJ
    Magaz, S
    Bautista, J
    Dominguez-Gil, A
    Mangues, MA
    Pla, R
    Rodriguez, JM
    Wood, MA
    VALUE IN HEALTH, 2002, 5 (06) : 539 - 540
  • [27] A Markov model to evaluate the coat effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases.
    Stephens, JM
    Aapro, MS
    Botteman, MF
    Hay, JW
    Brandman, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 44S - 44S
  • [28] Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid
    Jung, Klaus
    Miller, Kurt
    Wirth, Manfred
    Albrecht, Michael
    Lein, Michael
    EUROPEAN UROLOGY, 2011, 59 (04) : 604 - 612
  • [29] Treatment of Bone Metastases in Lung Cancer: The Actual Role of Zoledronic Acid
    Ricciardi, Serena
    de Marinis, Filippo
    REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (03) : 205 - 211
  • [30] Budget impact analysis of intravenous (IV) zoledronic acid vs. oral ibandronate or IV generic pamidronate in the prevention of bone complications in breast cancer patients with bone metastases: A UK NHS perspective
    Botteman, M
    Aapro, M
    Stephens, J
    Hay, JW
    Brandman, J
    VALUE IN HEALTH, 2005, 8 (03) : 345 - 345
12345